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Familial hypercholesterolemia is a genetic and metabolic disorder associated 
with an increased risk of morbidity and mortality. Two main types of familial 
hypercholesterolemia are distinguished: heterozygous familial hypercholester-
olemia and homozygous familial hypercholesterolemia. Homozygous familial 
hypercholesterolemia progresses much more aggressively with higher levels of 
LDL-C and higher risk of cardiovascular disease at earlier ages. The prognosis of 
homozygous familial hypercholesterolemia largely depends on the LDL-C levels. 
Reducing the LDL-C level is one of the primary goals of treatment patients with 
familial hypercholesterolemia. Effective control of LDL-C significantly reduces the 
cardiovascular morbidity and mortality. Understanding the factors likely to affect 
treatment adherence is paramount. Adherence to treatment can be improve when 
a genetic etiology is confirmed. Positive genetic test result has beneficial effects on 
adherence to pharmacotherapy and in achieving LDL-C levels reduction.
Keywords: familial hypercholesterolemia, adherence, illness perception, barriers, 
diagnose
1. Introduction
This chapter reviews the definition, etiology, course and treatment of familial 
hypercholesterolemia, and analyses the influence of some factors that may influ-
ence the early diagnosis of familial hypercholesterolemia and the treatment of 
familial hypercholesterolemia.
2. Definition and etiology of familial hypercholesterolemia
Familial hypercholesterolemia (FH) is a genetic and metabolic disorder that 
affects the metabolism of cholesterol [1–10].
Currently, the genes involved in HF are the following: low-density lipoprotein 
receptor (LDLR) gene, apolipoprotein B-100 (APOB) gene and proprotein con-
vertase subtilisin kexin type 9 (PCSK9) gene, LDLR adaptor protein 1 (LDLRAP1) 
gene [1–10]. See Table 1.
The mutation in LDLR gene, APOB gene and PCSK9 gene is inherited follow-
ing an autosomal dominant/autosomal co-dominant pattern and the mutation in 
LDLRAP1 gene is inherited following an autosomal recessive pattern [1–10].
Mutations of the genes cause defective LDL uptake and degradation, which 
in-turn leads to an elevation of plasma low-density lipoprotein-cholesterol (LDL-
C) level, producing the hypercholesterolemia phenotype. The chronic exposure to 
high levels of LDL-C lead to the development of atherosclerosis and cardiovascular 
disease at an early age [1–10].
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Two main types of HF are distinguished: heterozygous familial hypercholes-
terolemia and homozygous familial hypercholesterolemia. Heterozygous familial 
hypercholesterolemia is usually caused by a single pathogenic variant in one of the 
genes associated with familial hypercholesterolemia, mostly in LDLR. Homozygous 
familial hypercholesterolemia is caused by biallelic pathogenic variants, generally in 
LDLR [1–10].
3. Diagnosis of familial hypercholesterolemia
Familial hypercholesterolemia often diagnosed using the following diagnostic cri-
teria: UK Simon Broome System and the Dutch Lipid Clinic Network criteria [11–17].
The UK Simon Broome System Criteria can be applied in children/adolescents/
adults. The items included in Simon Broome System are the following: laboratory 
findings (total cholesterol or LDL-C), physical examination (tendon xanthomas), 
molecular diagnosis (mutation LDLR, APOB or PCSK9), and family history 
(myocardial infarction, raised total cholesterol) [11–17]. UK Simon Broome System 
Criteria is attached in Table 2.




LDLR LDL receptor 19p13.2 80–85%
APOB Apolipoprotein B100 2p24.1 5–10%
PCSK9 Proprotein convertase subtilisin kexin type 9 1p32.3 < 1%
LDLRAP1 LDL receptor adaptor protein 1 1p36.11 < 1%
Table 1. 
Genes involved in familial hypercholesterolemia.
Items Criterion
In adults (age ≥ 16): total cholesterol level > 290 mg/dL A
or LDL-C > 190 mg/dL
In children (age < 16): total cholesterol level > 260 mg/dL B
or LDL-C > 155 mg/dL
Tendon xanthomas in the patient or in a first- or
second-degree relative
DNA-based evidence of a mutation in LDLR, APOB, or C
PCSK9
Family history of myocardial infarction before age 50 D
in a second-degree relative, or before age 60 in a first degree
relative
Total cholesterol >290 mg/dL in a first- or second degree E
relative
C or A plus B: Definite familial hypercholesterolemia
A plus D or A plus E: Probable familial hypercholesterolemia
Table 2. 




The Dutch Lipid Clinic Network Criteria can be applied in adults. The items 
included in Dutch Lipid Clinic Network are the following: laboratory findings 
(LDL- C), physical examination (tendon xanthomas, arcus cornealis), molecular 
diagnosis (mutation LDLR, APOB or PCSK9), family history (atherosclerotic 
cardiovascular disease, tendon xanthomas, arcus cornealis, raised LDL- C), and 
patient history (coronary artery disease, cerebral or peripheral vascular disease) 
[11–17]. Dutch Lipid Clinic Network Criteria is attached in Table 3.
The diagnostic criteria mentioned differ in the items included and, in the items 
necessary to make a definitive FH diagnosis. In the Simon Broome criteria, a posi-
tive genetic test is sufficient for a definitive diagnosis of familial hypercholesterol-
emia. In the Dutch Lipid Clinic Network criteria, a positive genetic test should be 
accompanied by an additional item (for example, elevated LDL-C levels) to fulfill 
the definite diagnosis criteria [11–17].
Although all the criteria mentioned include LDL- C levels, there are variations in 
the cut-offs necessary for the diagnosis of familial hypercholesterolemia. It is worth 
mentioning that untreated LDL-C levels vary across genotypes. For example: levels 
are highest with two LDLR null alleles, lower with two LDLR defective alleles or 
two mutant PCSK9 alleles, and lowest with two mutant APOB alleles and in double 
heterozygotes [18–26].
Regardless of the diagnostic criterion used, before the diagnosis of familial 
hypercholesterolemia is confirmed, secondary causes of hypercholesterolemia 
should be excluded such as hypothyroidism, renal disease, nephrotic syndrome, 
liver disease and diets with extremely elevated saturated fat/cholesterol content. 
Items Score
First-degree relative with known premature atherosclerotic 1
cardiovascular disease (age < 55 in men,
age < 60 in women) or first-degree relative with LDL-C
> 95th percentile
First-degree relative with tendon xanthomas or arcus cornealis, 2
or child (under age 18) with LDL-C > 95th percentile
Premature coronary artery disease 2
Premature cerebral or peripheral vascular disease 1
Tendon xanthomas 6
Arcus cornealis before age 45 4
LDL-C ≥ 330 mg/dL 8
LDL-C between 250 and 329 mg/dL 5
LDL-C between 190 and 249 mg/dL 3
LDL-C between 155 and 189 mg/dL 1
Functional mutation in the LDLR, APOB, or PCSK9 gene 8
Score > 8 Definite familial hypercholesterolemia
Score between 6 and 8 Probable familial hypercholesterolemia
Score between 3 and 5 Possible familial hypercholesterolemia
Score < 3 Unlikely
Table 3. 
Dutch lipid clinic network criteria.
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Furthermore, there are several conditions with overlapping laboratory findings 
or family history features that might be considered when a diagnosed of familial 
hypercholesterolemia is suspected. For example: sitosterolaemia (xanthomas and 
hypercholesterolemia caused by an autosomal recessive pathogenic variant in 
ABCG5 or ABCG8) and lysosomal acid lipase deficiency (elevated LDL-C levels 
accompanied by fatty liver disease could be caused by an autosomal recessive 
pathogenic variant in LIPA) [27–29].
Once an individual is identified with familial hypercholesterolemia (index case) 
the cascade screening of family members of the known index case is recommend 
for identify new cases of familial hypercholesterolemia. Cascade screening could 
include LDL-C measurement, genetic testing, or both [11–17, 30].
Though the diagnosis of familial hypercholesterolemia can be performed 
without genetic testing (for example, using Simon Broome criteria), when a muta-
tion compatible with familial hypercholesterolemia is identified, genetic testing 
serves to confirm the diagnosis of FH. Furthermore, genetic testing could provide 
discrimination, at the molecular genetic level, between homozygous familial 
hypercholesterolemia and heterozygous familial hypercholesterolemia. Moreover, 
pre-test and post-test genetic counseling can facilitate patient’s interpretation of 
genetic test results [11–17].
The International Classification of Diseases, 10th Revision, has a specific 
diagnose criteria for homozygous familial hypercholesterolemia and heterozygous 
familial hypercholesterolemia (E78.01) [31].
The ICD10 criteria for heterozygous familial hypercholesterolemia are the 
following: LDL-C ≥ 160 mg/dL (4 mmol/L) for children or LDL-C ≥ 190 mg/dL 
(5 mmol/L) for adults and: a first-degree relative who is similarly affected or a first-
degree relative with positive genetic testing for an LDL cholesterol-raising defect in 
LDLR, APOB or PCSK9 [31].
The ICD10 criteria for Homozygous familial hypercholesterolemia are the 
following: LDL-C ≥ 400 mg/dL (10 mmol/L) and: one or both parents with clini-
cally diagnosed familial hypercholesterolemia or one or both parents with positive 
genetic testing for two identical (homozygous familial hypercholesterolemia) or 
non-identical (compound or double heterozygous familial hypercholesterolemia) 
LDL cholesterol-raising gene defects in LDLR, APOB or PCSK9 or one or both 
parents with autosomal recessive familial hypercholesterolemia [31].
Familial hypercholesterolemia is considered underdiagnosed. During the 
diagnosis process, some barriers might arise to early diagnosis of familial hyper-
cholesterolemia in patients and relatives. From medical point, for example: 
physician’s knowledge of FH diagnoses and treatment, the lack of a uniform 
clinical criteria for FH diagnosis, the availability of genetic testing, physician’s 
knowledge about screening methods (selective, opportunistic, universal, cas-
cade) and the identification of probable cases in different health care levels. 
From patient point, for example: some patients do not want a personal diagnosis 
to be disclosed to relatives, some parents experience feelings of guilt related to 
passing their mutation to their children, and many patients interpret their nega-
tive genetic test result as meaning their do not have FH hypercholesterolemia or 
that their FH hypercholesterolemia is not genetic and thus their relatives cannot 
have FH [1, 32].
Machine learning and deep learning approach could enhance the identification 
of familial hypercholesterolemia patients using electronic health record data. For 
example: the FIND FH model. This model recognizes the clinical phenotype for 
familial hypercholesterolemia and provides the framework for a HIPAA-compliant 




4. Course disease and treatment of familial hypercholesterolemia
The signs and symptoms of homozygous familial hypercholesterolemia and 
heterozygous familial hypercholesterolemia are similar. However, homozygous FH 
patients have higher levels of LDL-C and higher risk of cardiovascular disease. The 
disease progresses much more aggressively, the phenotype become clinical manifest 
earlier, and cardiovascular events occur at earlier ages in homozygous FH patients. 
Cardiovascular risk factors and lipoprotein(a) levels adversely affect the course of 
homozygous and heterozygous FH diseases increasing coronary heart disease rates 
[11–12, 14–16, 37–43].
The prognosis of homozygous familial hypercholesterolemia and heterozygous 
familial hypercholesterolemia largely depends on the LDL-C levels. Reducing the 
LDL-C level is one of the primary goals of treatment homozygous and heterozygous 
FH. Effective control of LDL-C significantly reduces the cardiovascular morbidity 
and mortality. To improve cardiovascular risk assessment, the use of imaging tech-
niques to detect asymptomatic atherosclerosis is recommended in both homozygous 
and heterozygous FH [11–12, 14–16, 41–43].
The carotid intima-media thickness is greater and aortic lesions can be seen 
identified in heterozygous FH patients between 8 to 10 years of age. During adoles-
cence about 25% of the adolescents with heterozygous FH have demonstrable coro-
nary artery calcium. Clinical manifestation of coronary heart disease can be evident 
in heterozygous FH patients during the third decade of life. Physical manifestations 
of sustained elevations of LDL-C (tendon xanthomas and corneal arcus) become 
apparent during adulthood [44–49].
At birth, homozygous familial hypercholesterolemia patients have a ≥ 4-fold 
increase in plasma LDL-C concentrations. Since early in life cholesterol deposits in 
tendons (xanthomas), in the cornea (corneal arcus) and around the eye (xanthe-
lasma). Furthermore, cholesterol deposits in coronary arteries, carotid arteries, 
aortic root, and valve. Therefore, coronary heart disease and supravalvular and 
aortic valve stenosis are possible causes of death. Young adults with homozygous 
familial hypercholesterolemia often require aortic valve replacement. Non-invasive 
imaging can be used to monitor atherosclerotic and aortic valve disease progression 
in homozygous FH patients and to adjusted treatment [50–55].
Treatment of FH is long-term and involves pharmacotherapy, lifestyle modifica-
tions and control other cardiovascular risk factors such as hypertension, diabetes, 
tobacco smoking, obesity, and sedentary behavior [12, 14–16, 41–42, 56–61].
Statins are the mainstay pharmacotherapy. However, if maximal tolerated dose 
of statin is used and LDL-C goal not achieved, statins usually combined with ezeti-
mibe. Additionally, if using statin-ezetimibe combination LDL-C goal not achieved, 
adding PCSK9 inhibitors is considered [12, 14–16, 41–42, 56–65]. The European 
Atherosclerosis Society/European Society of Cardiology plasma low-density 
lipoprotein-cholesterol goals [57] for patients with familial hypercholesterolemia 
are summarized in Table 4.
Patients with PCSK9 mutations are particularly responsive to PCSK9 inhibition. 
However, PCSK9 inhibitors had no effect on LDL cholesterol in those with two 
LDLR null alleles with homozygous familial hypercholesterolemia. Moreover, if at 
least one allele had residual LDLR activity, PCSK9 inhibitors lowered LDL choles-
terol in patients with homozygous familial hypercholesterolemia [66–69].
Incomplete/low adherence to treatment is associated with increased risk of 
cardiovascular disease. A proportion of FH patients fall short of full compliance or 
follow regimens inconsistently. Understanding the factors likely to affect treatment 
adherence is paramount [70–79].
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As well as in other chronic pathologies that require long-term treatment, psy-
chological and cognitive issues can influence adherence to treatment [70–79].
While there is no evidence of depression or anxiety in FH patients, instead there 
is evidence of cognitive deficits and mild cognitive impairment in FH patients. 
Deficits in executive functioning and memory may affect medication adherence 
because taking medicines involves developing and implementing a plan to adhere 
and remembering the plan (for example: the plan may require time-based (e.g., at 
8:00 p.m.) or event-based prospective remembering (e.g., with meals) and remem-
bering what medicine take and whether the medicine was taken). Furthermore, 
executive functions may affect the achievement of lifestyle modifications and 
maintain healthy behavior over time included in FH management [70–76].
Ilness perceptions may affect adherence to both lifestyle interventions and medi-
cations. Perception of illness/perception of risk may affect FH patient behavior. 
Risk perception may be changed by personal or familiar events, such as a cardio-
vascular event in the family, a change in or an onset of symptoms and becoming 
parent. Health staff need to recognize variation in patient’s risk perception because 
it can affect medical treatment [77–79].
Adherence to FH treatment can be improve when a genetic etiology is con-
firmed. Positive genetic test result has beneficial effects on adherence to pharma-
cotherapy and in achieving LDL-C levels reduction. Patients whose diagnosis was 
confirmed by genetic testing perceived diagnosis more accurate, believed more 
strongly that genes controlled their cholesterol and have higher perceived efficacy 
of medication. In children with FH, parents are critical in promoting treatment 
adherence [77, 80–85].
5. Conclusions
Although the diagnosis of familial hypercholesterolemia can be performed 
without genetic testing, knowledge about the genetic status of an individual with 
familial hypercholesterolemia can improve understand of risk and prognosis as well 
as improve managing familial hypercholesterolemia. Adherence to FH treatment 
can be improve when a genetic etiology is confirmed.
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